Novozymes Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Novozymes de 17.5% y 12% por año respectivamente. Se prevé que el BPA crezca en un 8.1% al año. Se espera que la rentabilidad financiera sea de 8.3% en 3 años.

Información clave

18.1%

Tasa de crecimiento de los beneficios

8.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Chemicals	23.6%
Tasa de crecimiento de los ingresos	12.2%
Rentabilidad financiera futura	7.7%
Cobertura de analistas	Good
Última actualización	08 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

LSE:0Q4U - Estimaciones futuras de los analistas y datos financieros pasados (DKK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	33,481	6,060	6,693	9,663	9
12/31/2025	31,320	5,207	5,679	8,648	9
12/31/2024	29,324	3,601	3,889	6,496	9
12/31/2023	17,899	3,024	2,097	4,152	N/A
9/30/2023	17,825	3,209	1,263	3,614	N/A
6/30/2023	17,736	3,425	616	3,248	N/A
3/31/2023	17,805	3,628	618	3,545	N/A
12/31/2022	17,553	3,676	1,116	4,006	N/A
9/30/2022	16,858	3,418	1,528	4,117	N/A
6/30/2022	16,252	3,108	1,946	4,007	N/A
3/31/2022	15,546	3,093	2,504	3,939	N/A
12/31/2021	14,951	3,146	2,822	4,062	N/A
9/30/2021	14,563	3,175	3,428	4,413	N/A
6/30/2021	14,233	3,044	3,209	4,197	N/A
3/31/2021	14,002	2,895	3,293	4,290	N/A
12/31/2020	14,012	2,825	3,415	4,355	N/A
9/30/2020	14,297	3,093	3,294	3,881	N/A
6/30/2020	14,570	3,020	3,463	3,997	N/A
3/31/2020	14,679	3,273	3,035	3,596	N/A
12/31/2019	14,374	3,154	2,629	3,196	N/A
9/30/2019	14,357	3,069	2,358	3,436	N/A
6/30/2019	14,311	3,238	2,616	3,768	N/A
3/31/2019	14,351	3,116	2,305	3,558	N/A
12/31/2018	14,390	3,226	2,287	3,679	N/A
9/30/2018	14,349	3,183	2,258	3,839	N/A
6/30/2018	14,271	3,194	1,954	3,649	N/A
3/31/2018	14,311	3,154	2,048	3,738	N/A
12/31/2017	14,531	3,119	2,371	4,063	N/A
9/30/2017	14,572	3,131	N/A	3,963	N/A
6/30/2017	14,382	3,063	N/A	3,883	N/A
3/31/2017	14,273	3,077	N/A	4,073	N/A
12/31/2016	14,142	3,050	N/A	3,840	N/A
9/30/2016	13,880	2,936	N/A	3,632	N/A
6/30/2016	14,012	2,929	N/A	3,248	N/A
3/31/2016	14,032	2,861	N/A	3,353	N/A
12/31/2015	14,002	2,823	N/A	3,339	N/A
9/30/2015	13,731	2,734	N/A	2,945	N/A
6/30/2015	13,393	2,630	N/A	3,308	N/A
3/31/2015	13,005	2,539	N/A	3,391	N/A
12/31/2014	12,459	2,526	N/A	4,525	N/A
9/30/2014	12,218	2,484	N/A	5,061	N/A
6/30/2014	11,970	2,413	N/A	4,791	N/A
3/31/2014	11,934	2,379	N/A	4,235	N/A
12/31/2013	11,746	2,200	N/A	2,599	N/A
9/30/2013	11,617	2,132	N/A	2,547	N/A
6/30/2013	11,519	2,085	N/A	2,531	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (17.5% al año) de 0Q4U es superior a la tasa de ahorro (1.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (17.5% al año) de 0Q4U crezcan más rápidamente que el mercado UK (12.2% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 0Q4U crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (12% al año) de 0Q4U crezcan más rápidamente que los del mercado UK (3.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 12% al año) de 0Q4U crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 0Q4U sea baja dentro de 3 años (8.3%).

Novozymes Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Novonesis Provides Sales Guidance for the Year 2024

Novonesis Provides Earnings Guidance for the Year 2024

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Recent updates

Now 22% overvalued after recent price rise

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Financial position

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Now 21% undervalued after recent price drop

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.8% yield

Independent Chairman recently bought kr.1.0m worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Upcoming Dividend of kr.5.25 Per Share

New 90-day high: kr.383

Novozymes A/S Announces Executive Appointments, Effective April 2021

Full year 2020 earnings released

Revenue misses expectations

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

New 90-day low: kr.338

Novozymes A/S Announces Executive Changes

New 90-day low: kr.357